Cerevel Therapeutics (NASDAQ:CERE) rose 2.2% amid a report that the Federal Trade Commission's closed door meeting on Monday is about Tempur Sealy's (NYSE:TPX) proposed acquisition of Mattress Firm. ...
Source LinkCerevel Therapeutics (NASDAQ:CERE) rose 2.2% amid a report that the Federal Trade Commission's closed door meeting on Monday is about Tempur Sealy's (NYSE:TPX) proposed acquisition of Mattress Firm. ...
Source Link
Comments